Spots Global Cancer Trial Database for Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Official Title: Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Study ID: NCT00575562
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Contact Details
Name: Jordan Berlin, M.D.
Affiliation: Ingram Professor of Cancer Research, Vanderbilt University
Role: PRINCIPAL_INVESTIGATOR
Name: Howard A Burris, III, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
